Genvor Inc

2022 Q4 Form 10-Q Financial Statement

#000149315223013372 Filed on April 24, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2021 Q4

Balance Sheet

Concept 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.46K
YoY Change
Cash & Equivalents $86.46K $0.00
Short-Term Investments
Other Short-Term Assets $15.40K $0.00
YoY Change
Inventory
Prepaid Expenses $1.331K
Receivables
Other Receivables
Total Short-Term Assets $101.9K $536.0K
YoY Change -80.99%
LONG-TERM ASSETS
Property, Plant & Equipment $17.11K $18.94K
YoY Change -9.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $17.11K -$536.0K
YoY Change -103.19%
TOTAL ASSETS
Total Short-Term Assets $101.9K $536.0K
Total Long-Term Assets $17.11K -$536.0K
Total Assets $119.0K $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $239.1K $3.500K
YoY Change 6731.43%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $48.75K
YoY Change
Long-Term Debt Due $1.132M
YoY Change
Total Short-Term Liabilities $1.670M $2.450M
YoY Change -31.83%
LONG-TERM LIABILITIES
Long-Term Debt $119.3K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $119.3K $344.2K
YoY Change -65.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.670M $2.450M
Total Long-Term Liabilities $119.3K $344.2K
Total Liabilities $1.789M $2.794M
YoY Change -35.95%
SHAREHOLDERS EQUITY
Retained Earnings -$16.47M -$69.74K
YoY Change 23512.68%
Common Stock $18.37K $26.03K
YoY Change -29.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.670M -$32.87K
YoY Change
Total Liabilities & Shareholders Equity $119.0K $556.9K
YoY Change -78.64%

Cashflow Statement

Concept 2022 Q4 2021 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001792941
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2021Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2022Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2021Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2022Q4 genvor Increase Decrease In Usda Crada Liability
IncreaseDecreaseInUsdaCradaLiability
usd
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2021Q4 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2021Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
333-234815
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
GENVOR INCORPORATED
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2054746
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
13155 Noel Road
CY2022Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75240
CY2022Q4 dei City Area Code
CityAreaCode
(214)
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
427-1921
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18422821 shares
CY2022Q4 us-gaap Cash
Cash
86463 usd
CY2022Q3 us-gaap Cash
Cash
296386 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
15398 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
101861 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
298386 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17107 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17565 usd
CY2022Q4 us-gaap Assets
Assets
118968 usd
CY2022Q3 us-gaap Assets
Assets
315951 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1132000 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1052000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
239102 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
516658 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3846 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3846 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
48750 usd
CY2022Q3 us-gaap Loans Payable Current
LoansPayableCurrent
48750 usd
CY2022Q4 genvor Usda Crada Liability
UsdaCradaLiability
246400 usd
CY2022Q3 genvor Usda Crada Liability
UsdaCradaLiability
246400 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1670098 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1867654 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
119333 usd
CY2022Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
89221 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
119333 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
89221 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1789431 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1956875 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18372821 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18372821 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38678155 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38678155 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18373 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
38678 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14777059 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14608815 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16467956 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16288417 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1670463 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1640924 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
118968 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
315951 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
6804 usd
CY2021Q4 us-gaap Professional Fees
ProfessionalFees
8253 usd
CY2022Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
37500 usd
CY2021Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
97500 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6448 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
458 usd
CY2021Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
458 usd
CY2022Q4 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
68820 usd
CY2021Q4 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
140660 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
113582 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
453319 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-113582 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-453319 usd
CY2022Q4 us-gaap Interest Expense Other
InterestExpenseOther
5846 usd
CY2021Q4 us-gaap Interest Expense Other
InterestExpenseOther
27772 usd
CY2022Q4 genvor Penalties
Penalties
30000 usd
CY2021Q4 genvor Penalties
Penalties
30000 usd
CY2022Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
30111 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-65957 usd
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57772 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-179539 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-511091 usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22471749 shares
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20000000 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-62540 usd
CY2021Q4 genvor Recapilitalization Rto Impact
RecapilitalizationRtoImpact
-2382746 usd
CY2021Q4 genvor Stockholders Equity Adjusted Balance
StockholdersEquityAdjustedBalance
-2445286 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000 usd
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1400 usd
CY2021Q4 genvor Stock Issued During Period Value For Cash
StockIssuedDuringPeriodValueForCash
737510 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-511091 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2017467 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1640924 usd
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-179539 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-179539 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1670463 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-179539 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-511091 usd
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
458 usd
CY2021Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
458 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
CY2022Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
30111 usd
CY2021Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2062 usd
CY2022Q4 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
13398 usd
CY2021Q4 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-55665 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-247555 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
23037 usd
CY2021Q4 genvor Increase Decrease In Usda Crada Liability
IncreaseDecreaseInUsdaCradaLiability
2800 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-409923 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-227069 usd
CY2022Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
50000 usd
CY2021Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
34375 usd
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150000 usd
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
570005 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200000 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
604380 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-209923 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
377311 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
296386 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7310 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86463 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
384621 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16467956 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-179539 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-409923 usd
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_ziUXPOjNW657" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2022Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
46386 usd
CY2022Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P7Y
CY2022Q4 genvor Late Fees
LateFees
30000 usd
CY2021Q4 genvor Late Fees
LateFees
30000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1432000 usd
CY2022Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1460000 shares
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
180668 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
1251333 usd
CY2022Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
5846 usd
CY2021Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
27772 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
9 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
9 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
9 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
9 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
18144112 shares
CY2022Q2 genvor Common Stock Retaining Share Value
CommonStockRetainingShareValue
1855888 shares
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2615256 usd
CY2022Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2572885 usd
CY2022Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-37703 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-204559 usd
CY2022Q4 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
4668 usd
us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
25326 usd
CY2022Q4 genvor Valuation Allowance
ValuationAllowance
42371 usd
genvor Valuation Allowance
ValuationAllowance
229885 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2615256 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2572885 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2615256 usd
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2572885 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2615256 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2572885 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2615256 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2572885 usd
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
19705 usd
CY2022Q3 us-gaap Assets Held In Trust
AssetsHeldInTrust
19705 usd
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2810 usd
CY2022Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5159 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
30240 usd

Files In Submission

Name View Source Status
0001493152-23-013372-index-headers.html Edgar Link pending
0001493152-23-013372-index.html Edgar Link pending
0001493152-23-013372.txt Edgar Link pending
0001493152-23-013372-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
genvor-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
genvor-20221231_cal.xml Edgar Link unprocessable
genvor-20221231_def.xml Edgar Link unprocessable
genvor-20221231_lab.xml Edgar Link unprocessable
genvor-20221231_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed